Shortages led to a 2.7% decrease in use of two common platinum-based chemotherapies: cisplatin and carboplatin.

The first-of-its-kind Center aims to advance new treatment approaches for patients with RAS mutant cancers.

Colorado University’s Eduardo Davila found that DNA-PK inhibitors stop inhibition of detectable molecules and also increase ...